MedTrace Logo

A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders

NCT04226963 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-09-28

No results posted yet for this study

Summary

This study aims to openly test the long-term safety, tolerability and effectiveness of repeated administration of IV, nasal spray and oral ketamine for treatment-resistant mood disorders.

Conditions

Interventions

DRUG

Ketamine

Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks) Ketamine will be given in intranasal spray twice weekly over a period of 4 weeks Ketamine will be given orally (solution 2.0mg/kg, 2.5mg/kg) twice weekly over a period of 4 weeks.

Sponsors & Collaborators

  • Medical University of Gdansk

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-04
Primary Completion
2022-07-04
Completion
2022-07-04

Countries

  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04226963 on ClinicalTrials.gov